Treat severe cases of infection at COV with XAV-19
- Funded by European Commission
- Total publications:0 publications
Grant number: 962036
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$2,551,927Funder
European CommissionPrincipal Investigator
DUVAUX OdileResearch Location
FranceLead Research Institution
XENOTHERAResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
This is letter of Intend to address the COVID-19 request by the European Union for the EIC accelerator. We have unique platform to develop polyclonal antibodies to address complex immune response such as the current pandemic. Over the course of the last 4 years we have developed pipeline of unique immunotherapies addressing various health needs, from transplantation to infectious disease. The coronavirus epidemic was developing we explored the possibility of developing treatment. Unfortunately given the time constraint and short notice we do not have the time to fully develop complete application we are submitting our response the current health need. We like the opportunity to further developed our plan with more time.